Excessive cardiovascular events impact populations with insulin resistance, insulinopenia, and renal dysfunction. Hyperlipidemia is causally related to cardiovascular disease and requires serum lipid level reduction. Focus on biochemical and molecular interactions of lipids toxic to the human organism may underpin future medication development. Focus on calcium ion channel blocking, glucose-lowering and immunosuppressive medications may lead to altered response to infecting organisms.